Haldol Withdrawal & Tapering Guide
haloperidol
Boxed Warning
Increased mortality in elderly patients with dementia-related psychosis.
In short
Haldol (haloperidol) is a Typical Antipsychotic with a half-life of ~18 hours (oral); 21 days (decanoate depot). Very slow taper recommended. Withdrawal symptoms, when they occur, usually begin 3-7 days (oral); weeks (depot) and settle within 4-8 weeks for acute symptoms. It is also sold as Haldol Decanoate.
- Class
- Typical Antipsychotic
- Half-life
- ~18 hours (oral); 21 days (decanoate depot)
- Common doses
- 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg tablets; 2mg/mL solution; 5mg/mL injection; 50mg, 100mg/mL decanoate depot
- Withdrawal onset
- 3-7 days (oral); weeks (depot)
- Typical resolution
- 4-8 weeks for acute symptoms
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Haloperidol is a high-potency first-generation (typical) antipsychotic for schizophrenia, acute psychosis, and Tourette syndrome. Higher rates of EPS and tardive dyskinesia than atypicals; lower metabolic burden.
0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg tablets; 2mg/mL solution; 5mg/mL injection; 50mg, 100mg/mL decanoate depot
Tablets: 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg; Oral solution: 2mg/mL; IM lactate: 5mg/mL; IM decanoate (depot): 50mg/mL, 100mg/mL
Category C
Mechanism of Action
Potent D2 antagonist with little serotonin or histamine activity. The "clean" D2 blocker — drives both efficacy and EPS.
Taper Notes
Very slow taper recommended. Watch for tardive movement disorders unmasking. Switching to atypical may smooth the taper for some patients.
Hyperbolic Tapering Guidance
High-potency D2 antagonists carry a meaningful tardive risk that is often irreversible. Discuss this risk explicitly during informed consent.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
3-7 days (oral); weeks (depot)
2-4 weeks
4-8 weeks for acute symptoms
Tardive dyskinesia can emerge during or after taper and may be permanent
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- QT-prolonging drugs — additive risk
- CYP3A4/2D6 inhibitors — increase haloperidol levels
- Levodopa — antagonizes effect
Contraindications
- Severe CNS depression
- Parkinson disease
- Known hypersensitivity
Toxicity
EPS (acute dystonia, parkinsonism, akathisia), tardive dyskinesia, NMS, QT prolongation, hyperprolactinemia, sedation. Tardive risk is substantial with chronic high-dose use.
Pharmacokinetics
ADME Profile
Hepatic via CYP3A4, CYP2D6.
~92%
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
The arithmetic of a proportional reduction
The Maudsley Deprescribing Guidelines and NICE NG222 describe reducing Typical Antipsychotic medications by a proportion of the previous dose rather than by a fixed amount, so each cut is smaller than the last. The table shows what that arithmetic produces at 10% per step, using 5 mg only as a worked example. How large each step is, how long it is held, and whether this pattern applies at all are decisions for the person and their prescriber.
| Step | % of starting dose | Worked example (5 mg start) |
|---|---|---|
| Start | 100% | 5 mg |
| Step 1 | 90% | 4.5 mg |
| Step 2 | 81% | 4.05 mg |
| Step 3 | 73% | 3.65 mg |
| Step 4 | 66% | 3.28 mg |
| Step 5 | 59% | 2.95 mg |
| Step 6 | 53% | 2.66 mg |
| Step 7 | 48% | 2.39 mg |
| Step 8 | 43% | 2.15 mg |
This is an illustration of a published method, not a schedule for anyone. It does not account for how long you have taken Haldol, your current dose, formulation, or history. TaperCommunity does not recommend doses or dose changes; those are agreed with your prescriber.
Frequently asked questions about Haldol
What are the withdrawal symptoms of Haldol (haloperidol)?
Common withdrawal symptoms of Haldol (haloperidol) include: rebound psychosis, cholinergic rebound (sweating, GI upset, insomnia), akathisia, tardive dyskinesia may emerge or worsen, withdrawal dyskinesia (especially in children). Symptom severity varies by individual, dose, and duration of use.
How should I taper off Haldol (haloperidol)?
Very slow taper recommended. Watch for tardive movement disorders unmasking. Switching to atypical may smooth the taper for some patients. High-potency D2 antagonists carry a meaningful tardive risk that is often irreversible. Discuss this risk explicitly during informed consent.
How long does Haldol withdrawal last?
Haldol withdrawal typically begins 3-7 days (oral); weeks (depot), peaks around 2-4 weeks, and resolves within 4-8 weeks for acute symptoms. Tardive dyskinesia can emerge during or after taper and may be permanent
Can I stop Haldol cold turkey?
Stopping Haldol abruptly is not recommended. Its half-life is ~18 hours (oral); 21 days (decanoate depot), and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Haldol stay in your system?
Haldol (haloperidol) has a half-life of ~18 hours (oral); 21 days (decanoate depot). As a rule of thumb, a drug is mostly cleared after about five half-lives. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Sources & References
Haldol (haloperidol) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D 2021 — A method for tapering antipsychotic treatment that may minimize the risk of relapse (Schizophrenia Bulletin)
- Tranter R, Healy D 1998 — Antipsychotic withdrawal symptoms: phenomenology and pathophysiology (Journal of Psychopharmacology)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Royal College of Psychiatrists — Antipsychotics — UK clinical guidance on antipsychotic prescribing and discontinuation
- Council for Evidence-Based Psychiatry (CEP UK) — Evidence-based critique of long-term antipsychotic prescribing
- Deprescribing.org — Antipsychotic deprescribing algorithm for insomnia and BPSD
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — antipsychotic tapering forum — Community archive of antipsychotic taper experiences
- Mad in America — antipsychotic archive — Independent journalism on antipsychotics and withdrawal
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of antipsychotic adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.